Skip to main content

Table 6 Univariate and multivariate analysis of factors influencing overall and progression-free survival

From: Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases

Covariate

Overall survival

Progression-free survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

HR (95% CI)

p-value

HR (95% CI)

p-value

Age (years)

 >70

1

   

1

   

 ≤70

1.1 (0.4-2.7)

0.81

NA

NA

0.8 (0.4-1.5)

0.56

NA

NA

Gender

 Female

1

   

1

   

 Male

1.6 (0.6-4.6)

0.31

NA

NA

1.2 (0.8-1.6)

0.25

NA

NA

Primary tumor

 non-CRC

1

   

1

   

 CRC

0.6 (0.2-1.4)

0.29

NA

NA

0.8 (0.5-1.6)

0.64

NA

NA

KPS

 ≤70%

1

   

1

   

 >70%

0.4 (0.2-1.1)

0.09

0.3 (0.1-0.8)

0.03

0.5 (0.3-0.9)

0.03

0.4 (0.2-0.7)

0.02

T-classification

 T≤2

1

   

1

   

 T>2

2.4 (0.8-6.8)

0.08

1.5 (0.4-5.0)

0.48

1.4 (0.7-2.8)

0.31

NA

NA

N-classification

 N0

1

   

1

   

N+

2.6 (0.9-7.3)

0.06

4.4 (1.2-15.6)

0.02

1.4 (0.7-2.7)

0.33

NA

NA

Time to first metastasis (months)

 <12

1

   

1

   

 ≥12

0.3 (0.1-0.9)

0.03

0.2 (0.1-0.7)

0.01

0.6 (0.3-1.2)

0.14

NA

NA

No. of metastases before SBRT

 <3

1

   

1

   

 ≥3

1.4 (0.6-3.3)

0.42

NA

NA

2.6 (1.3-5.1)

0.005

2.7 (1.4-5.4)

0.003

No. of affected organs

 1

1

   

1

   

 >1

1.6 (0.7-3.9)

0.24

NA

NA

1.1 (0.5-1.9)

0.97

NA

NA

Systemic therapy before SBRT

 Yes

1

   

1

   

 No

1.4 (0.3-6.3)

0.65

NA

NA

1.4 (0.5-4.1)

0.48

NA

NA

  1. NA not assessed, HR Hazard ratio, CI confidence interval, CRC colorectal cancer, KPS Karnofsky performance status, SBRT stereotactic body radiotherapy